KN-522: Clinical Implications and Insights Into Clinical Practice

EP: 1.NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer

EP: 2.Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data

EP: 3.BRCA Testing in Early-Stage and Metastatic Breast Cancer

EP: 4.OlympiA: Data Updates From SABCS 2024

EP: 5.Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors

Now Viewing

EP: 6.KN-522: Clinical Implications and Insights Into Clinical Practice

EP: 7.Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC

EP: 8.SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

Video content above is prompted by the following:

1. Dr. Shatsky please highlight the KN-522 study briefly before moving into discussion>>transition to>>Dr Shatsky asks Dr Degen:Based on updated KEYNOTE-522 data, how do you select patients for pembrolizumab-containing regimens?
   1. What factors influence your decision to recommend immunotherapy?
   2. How do you approach patients with borderline indications?